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Extracellular ATP controls key aspects of lung function via
activation of epithelial cell purinergic receptors, but howATP is
released from cells remains poorly understood. To identify
mechanistic components upstream of ATP release, we exam-
ined the effect of selectedGprotein coupled-receptor activation
on ATP release from lung epithelial cells. The protease-acti-
vated receptor (PAR) agonist thrombin elicited a rapidCa2-de-
pendent release of ATP from A549 cells. In contrast, the P2Y2
receptor agonist UTP caused negligible ATP release, despite
promoting a robust Ca2 response. Agonist-elicited ATP
release was associated with Rho activation and was reduced in
cells transfected with dominant negative mutants of p115-Rho
GEF or RhoA, and by inhibitors of Rho kinase (ROCK). How-
ever, RhoAactivation alone did not promoteATP release if tem-
porally separated from Ca2 mobilization. PAR3 was the only
PAR subtype detected in A549 cells by reverse transcription-
PCR. Transfection of cells with human PAR3 cDNA increased
thrombin-promoted ATP release, inositol phosphate forma-
tion, and RhoA activation. Conversely, small interference RNA
against PAR3 diminished thrombin-evoked responses. Throm-
bin-elicited ATP release was accompanied by an enhanced cel-
lular uptake of propidium iodide in a Ca2- and ROCK-depend-
ent manner and was inhibited by connexin/pannexin
hemichannel blockers. Our data suggest that thrombin pro-
motes ATP release from A549 cells via Rho- and Ca2-depend-
ent activation of connexin/pannexin hemichannels. The rele-
vance of these findings is highlighted by the observation that
exposure of primary cultures ofwell differentiated humanbron-
chial epithelial cells to thrombin resulted in robust ATP release,
which was inhibited by ROCK inhibitors and by connexin/
pannexin hemichannel blockers.
Nucleotides and nucleosides within the airway surface liquid
regulate mucociliary clearance activities, the primary innate
defense mechanism that removes foreign particles and patho-
gens from the airways (1–4). ATP activates the Gq-coupled
P2Y2 receptor (P2Y2-R)2 present on the airway epithelial cell
surface, promoting mucin secretion and ciliary beat frequency,
and inhibiting the epithelial Na channel (4–10). In addition,
ATP induces activation of a Ca2-activated Cl channel, via
P2Y2-R and, possibly, the ATP-gated ion channel P2X4-R (11–
13). Adenosine, generated from the hydrolysis of ATP in airway
surface liquid, activates the Gs-coupled A2b receptor, promot-
ing cAMP-regulated cystic fibrosis transmembrane conduct-
ance regulator Cl channel activity (14) and increasing cilia
beat frequency (5). In the distal lung, ATP and/or adenosine
(mainly via P2Y2-R and A2b receptor, respectively) stimulate
type II cell surfactant secretion (15), regulate alveolar ion trans-
port and fluid clearance (16), and contribute to alveolar remod-
eling and inflammation (17, 18). Although it is recognized that
ATP and adenosine are naturally occurring extracellular signals
that regulate key physiological components of lung function (1,
19), the origin of these signals in the extracellular milieu is
poorly understood.
Lung epithelia exhibit a complex cellular composition, and
thus, several mechanisms and pathways likely are involved in
the release of nucleotides into the airways and bronchoalveolar
space. Circumstantial evidence supports the involvement of
both secretory pathways and plasma membrane channels or
transporters in the cellular release of nucleotides from non-
excitatory tissues. However, unambiguous evidence for either
vesicular or conductive/transport mechanisms in the airways
and in most non-neural tissues is lacking. Moreover, the regu-
latory processes involved in ATP release are largely unknown
(20).
Although most studies with airway- or alveolar-derived epi-
thelial cells have relied on the use ofmechanical and/or osmotic
stimuli to promote ATP release, biochemical signals regulating
ATP release are less well defined. Recent data suggest that ATP
release in hypotonically swollen lung epithelial A549 cells
depends on the availability of intracellular Ca2 (21–23). How-
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ever, Ca2-mobilizing agents (e.g. ionomycin and UTP) pro-
moted only minor release of ATP from these cells, relative to
hypotonic shock (22, 23), suggesting that signals in addition to
Ca2 are required upstream of ATP release. This conclusion
was not restricted to epithelial cells. For example, studies from
our laboratory and those of others illustrated that Ca2 is nec-
essary but not sufficient to impart maximal ATP release from
1321N1 human astrocytoma cells (24, 25). In these cells, the
serine-protease thrombin promote robust Ca2-dependent
nucleotide release via protease-activated receptor-1 (PAR1),
and recent evidence indicates that Rho signaling is involved in
this response (26).
Because thrombin receptors are expressed in lung epithelial
cells (27), we reasoned that PAR activation might physiologi-
cally mediate regulated ATP release from these cells. In the
present study, we demonstrated that thrombin promotes
robust release of ATP from A549 lung epithelial cells via
PAR3 activation.We also investigated signaling mechanisms
and pathways involved in thrombin-evoked ATP release
from A549 cells as well as from physiologically relevant pri-
mary cultures of well differentiated human bronchial epithe-
lial (HBE) cells.
EXPERIMENTAL PROCEDURES
Reagents—Human -thrombin was purchased from Enzyme
Research Laboratories (SouthBend, IN). 2-Phenyl-1,2-benziso-
selenazol-3(2H)-one (ebselen), ,-methylene ATP (,-
metATP), arachidonylethanolamide, flufenamic acid, carben-
oxolone, and luciferase from Photinus pyralis were obtained
from Sigma. Fura-2-acetoxymethyl ester, 1,2-bis(o-aminophe-
noxy)ethane-N,N,N,N-tetraacetic acid-acetoxymethyl ester
(BAPTA-AM), and thapsigargin were purchased from Molec-
ular Probes (Eugene, OR). Luciferin was obtained from BD
Pharmingen (Franklin Lakes, NJ). The Rho Activation Assay
Biochem Kit was purchased from Cytoskeleton (Denver, CO).
Propidium iodide was purchased from Invitrogen. The PAR1-
activating peptide TFLLRNPNDK-amide and the PAR4-acti-
vating peptideAYPGKF-amide, respectively (hereafter referred
to as PAR1AP and PAR4AP, respectively) were synthesized at
the University of North Carolina (UNC) Microprotein
Sequencing and Peptide Synthesis Facility. myo-[3H]Inositol
(20 Ci/mmol) was obtained from Amersham Biosciences.
Other chemicals were from sources reported previously (1, 25).
Cell Culture—A549 lung epithelial cells were obtained from
the UNC Tissue Culture Facility and grown to confluence in
Dulbecco’s modified Eagle’s medium supplemented with 10%
calf serum (HyClone, Ogden, UT), 60 g/ml (100 IU/ml) peni-
cillin, and 100 g/ml streptomycin (Invitrogen). Cells were
grown on 35-mm plastic dishes for real-time ATP measure-
ments and on 24-well plastic plates for off-line ATP assays,
cAMP formation, and inositol phosphatemeasurements. RhoA
pulldown assays and confocal microscopy studies were per-
formed with cells grown on 100-mm Falcon plastic dishes and
8-well Lab-Tek II glass chamber slides (NalgeNunc Int., Naper-
ville, IL), respectively. Because a gradual decline in thrombin-
promoted responses was noted with passages, A549 cells were
used within passages 3–14. Polarized cultures of well differen-
tiated primary HBE cells (provided by the UNC Cystic Fibrosis
Center Center TissueCultureCore Lab)were grown on 12-mm
Transwell supports (Costar) and maintained at an air-liquid
interface that mimics the in vivo environment of the airway
epithelia, as previously described (1, 28).
Measurement of ATPRelease andHydrolysis—A549 ellswere
washed twice with Hanks’ balanced salt solution (HBSS) sup-
plemented with 1.6 mM CaCl2, 1.6 mM MgCl2, and 25 mM
HEPES, pH 7.4 (HBSS), and incubated for 1 h at 37 °C in
HBSS. For real-timeATPmeasurements in thin film (Fig. 1B),
cultures were transferred to a Turner TD-20/20 luminometer
(Turner Biosystems, Sunnyvale, CA). Luciferase (15–30  106
light units mg1) and luciferin (60 M) were added, and lumi-
nescence was monitored, as previously described (28). Off-line
ATP measurements were performed via a LB953 AutoLumat
luminometer (Berthold), as previously described (29). Calibra-
tion curves using known concentrations ofATPwere generated
at the end of each experiment.None of the reagents used during
ATP release measurements interfered with the luciferase reac-
tion. To assess ATP hydrolysis, 100 nM ATP was added to cells
in the absence or presence of 30 M ebselen and 300 M
-metATP, two previously characterized ATP hydrolysis
inhibitors (28–31). Samples were collected at various times,
and the resulting ATP concentration was measured as indi-
cated above. Primary HBE cells were rinsed and incubated with
300 l of mucosal and 500 l of basolateral HBSS (1), and ATP
release was measured off-line, as described above.
Inositol Phosphate Formation—A549 cells were labeled over-
night in inositol-free Dulbecco’s modified Eagle’s medium con-
taining 2 Ci/mlmyo-[3H]inositol (S.A., 20 Ci/mmol). Primary
HBE cells were labeled for 3 days in 500 l of basolateral and
100 l of mucosal medium containing 10 Ci/ml myo-
[3H]inositol. At the time of assay, 10 mM LiCl was added to
the cells for 10 min, followed by 20-min incubation in the
presence of drugs. Incubations were terminated by the addi-
tion of 0.75 ml of 50 mM formic acid and 0.25 ml of 150 mM
ammonium hydroxide. [3H]Inositol phosphates were sepa-
rated on Dowex anion-exchange columns and quantified as
previously described (32).
CalciumMobilization—A549 cells grown on glass coverslips
were loaded with Fura-2-acetoxymethyl ester for 30 min. Cells
were washed andmounted on a platform of a fluorometer-cou-
pled microscope, and fluorescence from 30–40 cells was
acquired alternately at 340 and 380 nm. Other details were as
previously described (28).
cAMP Quantification—Cells were rinsed, preincubated for
10 min in HBSS containing 200 M 3-isobutyl-1-methylxan-
thine, and subsequently challenged for an additional 10 min
with 30M forskolin and the indicated concentration of throm-
bin. The conversion of ATP to cAMP was quantified by high-
performance liquid chromatographic analysis of 1,N6-etheno-
adenine derivatives, as previously described (1).
RT-PCR Analysis—Total RNA was prepared using the
RNeasyMiniKit (Qiagen) and reverse-transcribed using Super-
Script III reverse transcriptase (RT, Invitrogen). RT-PCR was
performed using the following cycling conditions: 4 min/94 °C,
1 min/72 °C, 45 s/94 °C, 1 min/55 °C, and 1 min/72 °C; 36
cycles. PAR1 (GenBankTM M62424), PAR2 (GenBankTM
U34038), PAR3 (GenBankTMU92972), and PAR4 (GenBankTM
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AGCTAATTTTTG-3, respectively. Amplified products were
sequenced at the UNC Genome Analysis Facility.
Semi-quantitative PCR was performed in a LightCycler PCR
machine thermal cycler (10 min/95 °C; 5 s/55 °C, 8 s/72 °C; 45
cycles), using the LightCycler Fast start DNA master SYBER
Green I kit (RocheApplied Science).Melting curve analysis was
performed by heating the reactions from 65 °C to 95 °C at
0.11 °C intervals, and a fluorescence threshold (Ct) was deter-
mined using the LightCycler Software (version 4.0). Ct values
were adjusted for differences in amplification efficiencies. Glyc-
eraldehyde-3-phosphate dehydrogenase served as a house-
keeping gene for normalization between samples and was
included in each cycling run. The melting temperature of the
PCR product for each reaction was monitored to ensure that
only a single product of the correct size was amplified. Primer
pairs for PAR3 were as above. Primers for glyceraldehyde-3-
phosphate dehydrogenase were 5-GAAGTTGAAGGTCGG-
AGTCA-3 and 5-GATCTCGCTCCTGGAAGATG-3. The
average crossover point was determined using the Roche
Applied Science software. The relative expression levels of
PAR3 were calculated from the efficiency of the PCR reaction
and the crossing point, and normalized to the expression of the
reference gene, as previously described (33).
Overexpression of PAR3 and Dominant Negative Mutants of
RhoGEF and RhoA—A549 cells were transfected with
pcDNA3.1 empty vector, pmaxFP-Green-C GFP-expressing
vector, or vector containing the desired insert, using FuGENE
HD (Roche Applied Science). pcDNA3.1 vectors expressing
p115RGS and RhoA(T19N), and pBJ1 vector expressing HA-
tagged PAR3, were kindly provided byDr. T. K. Harden (34, 35)
and Dr. S. R. Coughlin (36), respectively. A transfection effi-
ciency of 70–80% was achieved, as assessed with the green flu-
orescent protein-expressing pmaxFP-Green-C vector.
Small Interference RNA (siRNA)—Oligonucleotides target-
ing human PAR3 and scrambled control (5-GGCATTCTTT-
GGATTCTTA-3 and 5-GTGAGTTCGTTCTCTATTA-3,
respectively) were purchased from Dharmacon, Inc. A549 cells
were transfected with 1g of oligonucleotide, using the Amaxa
Nucleofector DeviceTM and Cell Line Nucleofector Kit T
(Amaxa Biosystems, Gaithersburg, MD), following the manu-
facturer’s instructions. Transfected cells were grown in serum-
supplemented Dulbecco’s modified Eagle’s medium for at least
24 h, prior to assays.
Site-directedMutagenesis of PAR3—TheQuikChange II XL
site-directed mutagenesis kit (Stratagene, La Jolla, CA) was
used to generate a PAR3mutant isoform (PAR3196) resistant to
siRNA oligonucleotide knockdown. The sequence 5-GGCAT-
TCTTTGGATTCTTA-3wasmutated to 5-GGCATTTTTT-
GGGTTCTTA-3. Nucleotide changes and sequence integrity
of the expression vector were confirmed by sequencing. A549
cells were cotransfected with a pBJ1 expression vector bearing
PAR3196 (100 ng) and the indicated siRNA oligonucleotide,
using the Amaxa system, as described above.
RhoA Pulldown Assay—Measurements of GTP-bound RhoA
were performed using the Rho Activation Assay Biochem Kit
(Rhoketin assay), according to the manufacturer’s instructions.
Cell lysates and pulldown assays were resolved by SDS-PAGE
and transferred to polyvinylidene difluoridemembranes. RhoA
was detected by Western blot, using monoclonal anti-RhoA
antibody (1:500) provided by themanufacturer and IRdye800-
conjugated affinity-purified goat anti-mouse IgG (Rockland
Immunochemicals, Philadelphia, PA). Immunoblots were
revealed and quantified using the Odissey Infrared Imaging
System (LI-COR Biosciences, Lincoln, NE).
Myosin Light Chain Phosphorylation—Proteins were re-
solved by SDS-PAGE, and duplicated membranes were sep-
arately blotted with anti-phospho-MLC(Ser-19) antibody
(1:500) or anti-MLC (1:1000) antibodies (Cell Signaling
Technology Inc., Danvers, MA) by goat anti-rabbit Alexa
Fluor 680 secondary antibody (Invitrogen). Blots were
quantified as indicated above.
Uptake of Propidium Iodide—Cells were rinsed and chal-
lenged with agonist for 5 min, in the presence of 20 M pro-
pidium iodide. At the end of the incubation, the bathing
solution was replaced with HBSS containing 4% paraformal-
dehyde. Confocal images of nuclear staining and differential
interference contrast were acquired in a Leica SP5 confocal
microscope, using a 561 nm laser and a 20 lens (Leica, Ger-
many). The number of nuclei stained with propidium iodide
was calculated using Adobe Photoshop.
Data Analysis—Differences between means were deter-
mined by unpaired Student’s t test and were considered signif-
icant when p  0.05.
RESULTS
Thrombin Promotes ATP Release fromA549 Cells—The pau-
city of pharmacological approaches to trigger regulated nucle-
otide release poses a problem for studying the mechanism of
ATP release from lung epithelial cells. Quantification of ATP
release is further complicated by the presence of cell surface
ecto-ATPases that rapidly hydrolyze released ATP. By imple-
menting a protocol that quantifies ATP release in real-time in a
thin film near the cell surface (28), we investigated the action of
GPCR agonists on ATP release from lung epithelial cells.
Our initial screening revealed that the serine protease
thrombin promoted robust ATP release from lung carcinoma
A549 cells (Fig. 1). However, thrombin-evokedATP releasewas
evident only when ATP hydrolysis was inhibited. That is, in the
absence of drugs, ATP levels on resting cells stabilized around
9 2 nM and reached a level of 12 4 nM after the addition of
thrombin (30 nM, 10 min). In contrast, in the presence of ecto-
ATPase inhibitors (30 M ebselen and 300 M ,-metATP
(28)), extracellular ATP levels on resting cells increased mod-
estly to 22 7 nM in 10min, likely reflecting constitutive nucle-
otide release (24, 28, 29). Addition of thrombin in the presence
of ebselen and ,-metATP resulted in a robust increase of
extracellular ATP, which reached a concentration of 113  15
nM after 10 min (Fig. 1A). Based on these results, subsequent
measurements of agonist-promoted ATP release were per-
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formed in the presence of 30 M ebselen and 300 M
,-metATP.
PAR3 Mediates Thrombin-promoted ATP Release in A549
Cells—Thrombin and other serine-proteases activate a fam-
ily of four G protein-coupled receptors, referred as to pro-
tease-activated receptors (PAR1–PAR4). Thrombin acti-
vates PAR1, PAR3, and PAR4. The remaining member of the
PAR family, PAR2, is activated by trypsin and other pro-
teases but not by thrombin (reviewed in Refs. 37, 38). To gain
an insight into the PAR subtype(s) present in A549 cells,
RT-PCR studies were conducted. Fig. 1B illustrates that
PAR3 but not PAR1, PAR2, or PAR4 transcripts could be
amplified from A549 cells.
PARs are activated by proteolytic cleavage of the N-terminal
exodomain of the receptor. This cleavage generates a new N
terminus that functions as a tethered ligand, which binds to the
body of the receptor and promotes signaling (37, 38). Synthetic
peptides representing the newly formed N terminus selectively
activate PAR1, PAR2, and PAR4, independent of receptor
cleavage. Human PAR3 is not activated by PAR3-mimicking
peptides, which suggests that PAR3 activation requires proteo-
lytic cleavage at the N-terminal exodomain (36). Fig. 1C shows
that thrombin, but not PAR1- and
PAR4-activating peptides (PAR1AP
and PAR4AP, respectively), elicited
ATP release in a concentration-
dependent manner. Enhanced ATP
release was readily observed in
response to 1 nM thrombin and was
maximal with 30 nM thrombin
(EC50  7 nM).
Because activation of thrombin
receptors results in phospholipaseC
activation (36, 39, 40), we investi-
gated the effect of thrombin and
PAR-activating peptides on inosi-
tol phosphate formation, using
[3H]inositol-labeled A549 cells. Fig.
1D shows that thrombin promoted
[3H]inositol phosphate formation
with a potency (EC50  6.3 nM) sim-
ilar to that observed for ATP
release. PAR1AP or PAR4AP pro-
moted negligible [3H]inositol phos-
phate formation (Fig. 1D). Alto-
gether, the data in Fig. 1 suggest that
PAR3 in the only thrombin receptor
present in A549 cells.
To more definitively assess the
involvement of PAR3 in thrombin-
elicited ATP release, the effect of
PAR3 overexpression/suppression
was examined. Overexpression of
PAR3 conferred enhanced throm-
bin-elicited ATP release and inosi-
tol phosphate formation to A549
cells, relative to vector-transfected
cells (Fig. 2). Gain in thrombin-pro-
moted ATP release was noted in cells transfected with as low as
10 ng of PAR3 cDNA/well and was robust with 100–300 ng of
cDNA/well (Fig. 2A). The potency of thrombin in eliciting ATP
release and inositol phosphate formation increased by 5-fold
(EC50  1.1 nM) and 7-fold (EC50  1.2 nM), respectively, in
cells transfected with 100 ng PAR3 cDNA, relative to vector-
transfected cells (Fig. 2, B and C).
The contribution of PAR3 to ATP release from A549 cells
was directly examined by targeting the endogenous PAR3 via
siRNA. Transfection of A549 cells with a PAR3-selective (but
not its scramble) siRNA oligonucleotide resulted in 60%
decrease of PAR3 transcripts, as judged by quantitative PCR
(Fig. 3A). Thismanipulation also resulted in50% inhibition of
thrombin-evoked inositol phosphate formation (Fig. 3B) and
ATP release (Fig. 3C). The PAR3 siRNA approach had no effect
onGPCR (other than PAR3)-mediated signaling, becauseUTP-
evoked inositol phosphate formation was unaffected in PAR3
siRNA-transfected cells (vehicle, 1155  178 cpm; UTP,
5430  177 cpm; PAR siRNA-transfected cells: vehicle, 1195 
164 cpm; UTP, 5869 257 cpm;mean S.D., n 4). To verify
that the siRNA approach did not knock down downstream
effectors of PAR3, cells were cotransfected with PAR3196, a
FIGURE 1. Thrombin-promoted ATP release and inositol phosphate formation in a PAR1- and PAR4-
independnet manner. A, extracellular ATP concentrations were measured in real-time, in the absence or
presence of 30 M ebselen and 300 M -metATP (added at t  0), as described under “Experimental Proce-
dures.” Thrombin (30 nM) was added at t  10 min. Values are the mean  S.E. of eight independent measure-
ments. B, PAR mRNA expression in A549 cells was determined by RT-PCR analysis. Plasmids expressing the
indicated PAR were used as positive controls (Ctrl). Results are representative of nine independent A549 cell
RNA preparations. C, cells were stimulated for 5 min with thrombin, PAR1AP, or PAR4AP, and extracellular ATP
measured was off-line, as described under “Experimental Procedures.” Values are the mean  S.E. of three
independent measurements performed in sextuplicate. D, myo-[3H]inositol-labeled cells were incubated for 20
min with the indicated agonist, and the resulting [3H]inositol phosphates were separated and quantified, as
described under “Experimental Procedures.” Results are from three independent experiments performed with
quadruplicate samples.
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PAR3 cDNAmutant resistant to the PAR3 siRNA oligonucleo-
tide. PAR3196-mediated ATP release was not affected by PAR3
siRNA (Fig. 3D). Altogether, these results indicate that PAR3 is
themajor contributor to thrombin-evokedATP release inA549
cells.
Ca2 Is Necessary but Not Sufficient for Agonist-evoked ATP
Release—Cytosolic Ca2 is an important regulator of ATP
release in many cells. For example, in excitatory tissues, ATP is
released from ATP storage granules via Ca2-regulated exocy-
tosis (20). Ca2-dependent ATP release has been also reported
in cells lacking specialized ATP storage granules (21–23, 25,
41). Preincubation of A549 cells with 10 M BAPTA-AM or 1
M thapsigargin resulted in major
inhibition of thrombin-promoted
ATP release (Fig. 4A), suggesting




release requires a Ca2-dependent
step, we asked whether Ca2-mobi-
lizing receptors other than PARs
(e.g. P2Y2-R) promote ATP release
from these cells. Incubation of A549
cells with 100 M UTP resulted in
enhanced extracellular ATP con-
centrations, but the effect ofUTPon
ATP levels was modest, relative to
thrombin (Fig. 4B). To investigate
whether differences in UTP- versus thrombin-elicited second
messenger signaling have accounted for the observed differ-
ences in agonist-promoted ATP release, UTP-promoted phos-
phoinositide breakdown was examined. UTP promoted inosi-
tol phosphate formation responses that were greater than
thrombin responses. Nucleotide-evoked inositol phosphate
formation, with potency order UTPATP		ADP, UDP, was
consistent with P2Y2-R expression (Fig. 4C). RT-PCR analysis
confirmed the expression of P2Y2-R transcripts in A549 cells
(not shown). Importantly, UTP promoted Ca2 mobilization
responses in Fura-2-acetoxymethyl ester-loaded A549 cells
that were similar or greater in magnitude than thrombin (Fig.
4D). Altogether, the results suggest that receptor-promoted
Gq/phospholipase- activation/Ca2 mobilization alone was
not sufficient to elicit ATP release from A549 cells.
Thrombin-induced ATP Release Is Independent of Gi
Activation—It has been established that PAR1 interacts with
Gq, Gi, and G12/13 families of G proteins (37, 42). Unlike PAR1,
the G protein coupling of PAR3 is poorly defined. The fact that
thrombin promotes phosphoinositide breakdown in a PAR3-
dependent manner in A549 cells (Figs. 2 and 3), as well as in
PAR3-transfectedCOS-7 cells (36), suggests that PAR3 couples
to Gq. However, as mentioned above, signaling in addition to
Gq/phospholipase C/Ca2 is likely involved in thrombin-
evoked ATP release from A549 cells. To assess Gi activation in
thrombin-stimulated A549 cells, thrombin-promoted inhibi-
tion of cAMP formation was examined. Addition of 30 M for-
skolin (in the presence of the phosphodiesterase inhibitor
3-isobutyl-1-methylxanthine) markedly enhanced cAMP for-
mation inA549 cells (control, 8 2 pmol/well; forskolin, 103
6 pmol/well), which was inhibited (27%maximal inhibition) by
thrombin, in a dose-dependent manner (supplemental Fig.
S1A). Pertussis toxin, which ADP-ribosylates and inhibits Gi
proteins, reversed the inhibitory effect of thrombin on forsko-
lin-elicited cAMP formation (supplemental Fig. S1A). Pertussis
toxin failed to inhibit thrombin-promoted ATP release (sup-
plemental Fig. S1B). Thus, although these results illustrated the
presence of a Gi-coupled thrombin receptor in A549 cells, ATP
release was not regulated by Gi activation. Consistent with
these results, preincubation of cells with the phosphatidylino-
sitol 3-kinase inhibitor wortmannin (200 nM/15 min) had no
FIGURE 2. PAR3 overexpression enhances thrombin-elicited ATP release and inositol phosphate forma-
tion in A549 cells. A, cells were transfected with the indicated amount of cDNA. Forty-eight hours post trans-
fection, cells were preincubated with ebselen and -metATP as in Fig. 1 and incubated for 5 min with 30 nM
thrombin or vehicle. B and C, cells transfected with 100 ng of PAR3 cDNA were stimulated for 5 min (B) or 20 min
(C) with the indicated concentration of thrombin, and ATP release and inositol phosphate formation were
measured as described in Fig. 1, C and D, respectively. The data represent the mean  S.E. of at least three
independent experiments performed in quadruplicate.
FIGURE 3. PAR3 mediates thrombin-elicited ATP release and inositol
phosphate formation in A549 cells. A, PAR siRNA reduces PAR3 mRNA
expression. B, effect of PAR3 siRNA on thrombin (30 nM)-promoted inositol
phosphate formation. C, ATP release was measured in cells transfected with
either PAR3 siRNA or its scramble oligonucleotide. D, cells transfected as
above were cotransfected with empty-vector or siRNA-resistant PAR3196
cDNA (PAR3R). ATP was measured off-line, 5 min after the addition of vehicle
or 30 nM thrombin, in the presence of 30 M ebselen and 300 M -metATP.
The data represent the mean  S.E. of three separate experiments performed
in triplicate; p  0.05.
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effect on thrombin-elicited ATP
release (supplemental Fig. S1B).
Thus, phosphatidylinositol 3-ki-
nase, known to be activated by /
subunits of Gi proteins downstream
of PAR activation (43), was not
involved in thrombin-promoted
ATP release in A549 cells.
Thrombin Promotes ATP Release
via G12/13-mediated RhoGEF/RhoA
Activation—Rho GTPases are well
known downstream effectors of
G12/13, via G12/13 activation of gua-
nine nucleotide exchange factors
(GEFs) of Rho (RhoGEF) (reviewed
in Ref. 44). Addition of thrombin
to A549 cells caused a rapid and
robust activation of RhoA, meas-
ured by the RhoA pulldown assay.
RhoA activation was observed as
early as 30 s post-thrombin addi-
tion and was robust after 90 s (Fig.
5A). Thrombin-elicited RhoA
activation increased considerably
in cells transfected with PAR3
(Fig. 5A) and was reduced by PAR3
siRNA (Fig. 5B).
To examine the possibility that
PAR3-elicited ATP release involved
activation of G12/13/RhoGEF/Rho,
A549 cells were transfected with
dominant negative mutants of Rho-
GEF and RhoA. Transfection of
A549 cells with p115RGS, a G12/13-
inhibitory protein derived from the
RGS domain of p115-RhoGEF (34),
impaired thrombin-promoted ATP
release (Fig. 6A). Similarly, transfec-
tion of cells with the RhoAmutant RhoA(T19N), which tightly
binds to RhoGEF but does not promote downstream effector
activation (45), markedly inhibited thrombin-elicited ATP
release (Fig. 6A). Control experiments indicated that thrombin-
promoted inositol phosphate formation was not significantly
affected by p115RGS or RhoA(T19N) transfections (Table 1).
Rho kinases (ROCKs) are important effectors of Rho (46).
Preincubation of A549 cells with the ROCK inhibitor Y27632
resulted in dose-dependent inhibition of thrombin-promoted
ATP release, with maximal inhibition observed with 1 M
Y27632 (Fig. 6, B and D). H1152, a more potent and selective
ROCK inhibitor than Y27632 (47), also reduced ATP release in
response to thrombin (Fig. 6B). ROCK activation is known to
promote MLC phosphorylation, e.g. by phosphorylating and
inactivating MLC phosphatase (48). Consistent with the possi-
bility that MLC is an effector of ROCK upstream of ATP
release, thrombin-promoted MLC phosphorylation was
observed and was inhibited by 100 nM H1152 (Fig. 6C). Fur-
ther, ML-7 (1 M), an inhibitor of the Ca2/calmodulin-de-
pendent MLC kinase (MLCK) (49), reduced MLC phospho-
FIGURE 4. Ca2 is necessary but not sufficient by itself for agonist-evoked ATP release. A, cells were
preincubated for 20 min with vehicle (Ctrl), 1 M thapsigargin (Tg), or 10 M BAPTA-AM (BAPTA), and ATP
concentrations were measured off-line, 5 min following the addition of vehicle or 30 nM thrombin. Ebselen (30
M) and -metATP (300 M) were added to cells 5–10 min prior addition of vehicle/thrombin. The data
represent the mean  S.E. of at least six separate experiments performed in quadruplicate. B, cells were
incubated with vehicle, 30 nM thrombin, or 100 M UTP, and ATP concentrations were measured as above.
C, myo-[3H]inositol-labeled cells were incubated for 20 min with the indicated drugs, and the resulting
[3H]inositol phosphates were separated and quantified as in Fig. 1D. Results are from four independent exper-
iments performed with quadruplicate samples. D, cells were loaded with Fura-2-acetoxymethyl ester for 30
min and stimulated with 30 M thrombin or 100 M UTP. Fluorescence from 30 – 40 cells was acquired as
described under “Experimental Procedures.” Representative tracings are illustrated; similar results were
obtained in six independent experiments.
FIGURE 5. PAR3 promotes RhoA activation. A, total RhoA and RhoA-GTP
were measured in A549 cells transfected with 100 ng of empty vector or PAR3
cDNA, as in Fig. 2. RhoA activation was visualized by the pulldown assay (left),
as described under “Experimental Procedures.” RhoA activation is expressed
as -fold increase over control (vector, t  0); values are the mean  S.E. of ten
independent experiments (right). B, PAR3 siRNA reduced thrombin (30 nM, 5
min)-promoted RhoA activation. The Western blot (left) is representative of
four experiments performed under similar conditions. Values (right) are
expressed as -fold increase over vehicle in scramble-transfected cells
(mean  difference to mean, n  4).
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rylation (Fig. 6C) and impaired ATP release (Fig. 6D) in
thrombin-stimulated A549 cells. None of these inhibitors
affected the ability of thrombin to promote inositol phos-
phate formation (Table 1).
Altogether, these data illustrate that Rho activation is necessary
for PAR3-promoted ATP release in A549 cells. The data also sug-
gest that Rho actions aremediated, at least in part, by ROCK acti-
vation, likely facilitatingMLC phosphorylation byMLCK.
ATP Release Requires the Coordinated Action of Ca2- and
Rho-dependent Pathways—Because P2Y2-R stimulation has
been linked to RhoA activation in endothelial cells (50), we
asked whether UTP promotes RhoA activation in A549 cells
and, if so, whether such activation differed from that of throm-
bin. Fig. 7A shows that incubation of A549 cells with 100 M
UTP resulted in RhoA activation that was similar in magnitude
to thrombin. However, unlike the rapid effect of thrombin,
UTP-promoted RhoA activation was observed only after 15
min. Thus, although thrombin promoted RhoA activation and
Ca2 mobilization (Figs. 4, 5, and 7) with overlapping time
frames (30–90 s), UTP-induced RhoA activation was dissoci-
ated in time from Ca2 responses (Figs. 4 and 7).
We hypothesized that Rho activation and Ca2 mobilization
must be temporally coordinated to promote ATP release. To
assess this hypothesis, cells were preincubated for 15 min with
100 MUTP (to achieve robust RhoA activation), followed by a
5-min challengewith the Ca2 ionophore ionomycin. As a con-
trol, cells were preincubatedwith vehicle. Fig. 7B illustrates that
addition of ionomycin (either alone or in combination with
UTP) to untreated cells resulted in negligible ATP release. In
contrast, addition of ionomycin to cells that were preincubated
for 15minwithUTP resulted in robust release of ATP (Fig. 7B).
The simplest interpretation of these results is that maximal
ATP release requires synchronized activation of Rho and Ca2
signaling.
Thrombin Promotes Opening of Connexin-like Hemichannels
in a Ca2 and ROCK-dependent Manner—Connexin and
pannexin hemichannels have been proposed as a electrodiffu-
sive pathway for the release of ATP under various experimental
conditions (51, 52). Connexin (but not pannexin) hemichannels
close at millimolar extracellular Ca2 ([Ca2]ex) and open
when [Ca2]ex is lowered. Exposure to lowered extracellular
FIGURE 6. Thrombin-elicited ATP release is mediated by G12/13/RhoA/
ROCK. A, ATP release was quantified in P115-RGS-, or RhoA(T19N)- trans-
fected cells, after 5-min incubation with 30 nM thrombin or vehicle. Values are
the mean  S.E. of four independent experiments performed in quadrupli-
cate. B, cells were preincubated for 1 h with the indicated concentrations of
H1152 or Y27632, and ATP release was measured after 5-min incubation with
30 nM thrombin or vehicle. The data are plotted as the percent of stimulation
observed with 30 nM thrombin, in the absence of inhibitors. Values the
mean  S.E. from five separate experiments performed in quadruplicate.
C, the effect of 100 nM H1152 or 1 M ML-7 on thrombin-promoted MLC
phosphorylation is illustrated by a Western blot (top). Quantification of p-MLC
is indicated in the bottom; mean  S.D., n  3. D, effect of 1 M ML-7 on
thrombin-promoted ATP release. Values are the mean  S.D. from at least
three independent experiments performed in quadruplicate. *, significant inhi-
bition of thrombin responses, p  0.05. ATP measurements were performed in
the presence of ebselen and -metATP as indicated in previous figures.
TABLE 1
Thrombin-promoted inositol phosphate formation is not affected by
Ca2, Rho, or connexin/pannexin inhibitors
myo-
3HInositol-labeled A549 cells were challenged for 20 min with 30 nM throm-
bin, and the resulting inositol phosphates were quantified as indicated under
“Experimental Procedures.” Transfections and preincubations with pharmacologi-
cal inhibitors were as in Fig. 8.
Inhibitor Mean  S.D. n
cpm
Control 1638  296 8
Thrombin 3187  516 8
Thrombin P115-RGS 3516  251 4
Thrombin RhoA(T19N) 2680  82 4
Thrombin 1 M H1152 3536  496 8
Thrombin 10 M Y27632 3269  202 8
Thrombin 1 M ML-7 2924  227 4
Thrombin 100 M Anandamide 3361  235 4
Thrombin 100 M Flufenamic Acid 3076  467 4
Thrombin 10 M Carbenoxolone 3316  289 8
FIGURE 7. RhoA activation and Ca2 mobilization act in concert to pro-
mote ATP release. A, RhoA activation was measured and quantified in A549
cells stimulated for the indicated times with 30 nM thrombin or 100 M UTP.
The results (-fold increase relative to untreated cells) represent the mean 
S.E. of five separate experiments. B, ATP release was measured in cells prein-
cubated with vehicle or 100 M UTP for 15 min, and challenged for additional
5 min with the indicated drugs. The data represent the mean  S.E. of three
separate experiments performed in quadruplicate. Ebselen and -metATP
were added as indicated in previous figures.
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divalent ion conditions is a well known procedure to potentiate
or trigger the opening of connexin hemichannels, leading to
ATP release (53, 54). In addition, both pannexins and connex-
ins have been reported to conduct ATP at physiologically rele-
vant [Ca2]ex (51, 52).
While investigating the role of calcium in PAR-stimulated
responses, we observed that removal of [Ca2]ex resulted in
enhanced ATP release from resting and thrombin-stimulated
A549 cells (Fig. 8A), suggesting that connexin hemichannels are
present on the A549 cell surface. This observation led us to
investigate the possibility that hemichannels were involved in
the release of ATP from thrombin-stimulatedA549 cells, under
normal [Ca2]ex conditions. Fig. 8B illustrates that throm-
bin-induced ATP release, assessed in the presence of 1.6 mM
[Ca2]ex, was markedly inhibited by non-selective connexin/
pannexin inhibitors (100 M arachidonylethanolamide, 100
M flufenamic acid, and 10 M carbenoxolone). Control
experiments indicated that none of the hemichannel inhibi-
tors affected thrombin-evoked inositol phosphate formation
(Table 1).
To further assess the possibility that thrombin promoted
connexin/pannexin hemichannel opening, the uptake of the
hemichannel-permeable reporter dye propidium iodide was
investigated. Propidium iodide displays low intrinsic fluores-
cence, but its fluorescence increases 20- to 30-fold upon bind-
ing to nucleic acids. Under resting conditions, a small popula-
tion (4%) of A549 cell nuclei were labeled with propidium
iodide, but dye uptake increasedmarkedly (3- to 4-fold) follow-
FIGURE 8. Involvement of connexin/pannexin hemichannels in thrombin-promoted ATP release from A549 cells. A, cells were preincubated for 2 min in
EGTA/Ca2-buffered solutions, and extracellular ATP was measured after an additional 5-min incubation with vehicle or 30 nM thrombin. The data represent
the mean  S.E. of three separate experiments performed in quadruplicate. B, changes in ATP concentrations were measured in cells preincubated for 15 min
with 100 M arachidonylethanolamide, 100 M flufenamic acid (FFA), or 10 M carbenoxolone (CBX), and challenged for 5 min with vehicle or 30 nM thrombin.
Values represent the mean  S.E. of at least six separate experiments performed in quadruplicate. All ATP measurements were in the presence of 30 M ebselen
and 300 M -metATP. C, uptake of cells with propidium iodide was assessed after 5-min incubation with vehicle or 30 M thrombin. The images represent
an overlay of propidium iodide (red)-associated nuclear fluorescence and differential interference contrast. D, A549 cells were preincubated with vehicle or
with 10 M carbenoxolone (CBX, 15 min), 10 M Y27632 (45 min), 1 M H1152 (45 min), 10 M BAPTA-AM (20 min), or with 1 M ML-7 (45 min), and challenged
for 5 min with no agonist (Ctrl), 30 nM thrombin, 100 M UTP, or 1 mM ATP in the presence of propidium iodide. Cells were fixed, and images were taken and
analyzed by confocal microscopy. Dye uptake is expressed as the percent of nuclei displaying red fluorescence. The data are the mean  S.E., n  4. Similar
results were obtained in at least three separate experiments performed in quadruplicate. Incubations in B–D were in HBSS containing 1.6 mM CaCl2. Bar, 100
m. *, significant inhibition of thrombin responses, p  0.05.
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ing a 5-min incubation of the cells with 30 nM thrombin (Fig.
8C). Unlike propidium iodide, which has a relatively small
molecular mass (668.4 Da), the endocytosis marker fluorescein
Dextran (3000–10000 Da) was not taken up by thrombin-stim-
ulated A549 cells (not shown). Consistent with connexin/
pannexin hemichannel involvement in agonist-promoted dye
uptake, carbenoxolone inhibited the effect of thrombin on
nucleus-associated fluorescence (Fig. 8D). Particularly relevant
to our present study was the observation that thrombin-in-
duced dye uptake was markedly inhibited by ROCK (Y26632
andH1152) orMLCK inhibitors (ML-7), and BAPTA-AM (Fig.
8D). Unlike thrombin, UTP (100 M) and ATP (1 mM) pro-
moted no changes in dye uptake (Fig. 8D), indicating that
P2Y2-R activation did not suffice to induce hemichannel open-
ing. Moreover, lack of effect of 1 mM ATP on propidium iodide
uptake argues against the possibility that the pore forming
P2X7-R (55) is expressed in these cells. Altogether, these data
suggest that thrombin promoted Ca2- and Rho-regulated
ATP release via connexin/pannexin hemichannels in A549
cells.
Thrombin PromotesMucosal ATPRelease fromPrimary Cul-
tures of Well Differentiated HBE Cells—Having identified
mechanistic components involved in ATP release in A549 cells,
we asked whether observations made with these cells apply to
physiologically relevant airway epithelia. Therefore, we exam-
ined the effect of thrombin on ATP release from polarized cul-
tures of well differentiated primary HBE cells. Addition of 30
nM thrombin to the mucosal compartment had no effect on
ATP release (not shown). In contrast, thrombin added to the
basolateral compartment of HBE cultures resulted in a robust
release of ATP through the apical (but not basolateral) surface
(Fig. 9A). These data are in agreement with previous observa-
tions indicating that (i) ATP release occurs through elements
that segregate to the apical domain after cell polarization (1,
33), and (ii) PARs are expressed at the basolateral membrane of
polarized lung epithelial cells (56–58). The identity of the PAR
evoking ATP release in primary HBE cells remains to be eluci-
dated. As in A549 cells, the effect of thrombin on ATP release
was markedly reduced in HBE cells
that were preincubated with the
ROCK inhibitor H1152, the MLCK
inhibitor ML-7, or the connexin/
pannexin hemichannel blocker car-
benoxolone (Fig. 9B). Unlike throm-
bin, mucosal UTP caused no ATP
release from HBE cells (Fig. 9A),
despite the well established pres-
ence of P2Y2 receptors on these cells
(59, 60) (see Fig. 9C).
Regardless the lack of effect of
UTP on ATP release (Fig. 9A), the
presence of phospholipase C-acti-
vating P2Y2 receptors on the apical
surface of HBE cells (59, 60) sug-
gests that ATP released onto the
thin liquid film covering the muco-
sal airway epithelial cell surface con-
tributed, at least in part, to PAR-
evoked signaling. To test this possibility, the effect of the
ATPase enzyme apyrase on thrombin-elicited [3H]inositol
phosphate formation was assessed. To minimize dilution of
released ATP, the mucosal surface liquid volume was reduced
to 100 l/well (83 l/cm2 culture). Inclusion of 5 units of
apyrase in this thin airway surface liquid resulted in small (21%)
but reproducible decrease of [3H]inositol phosphate formation
in response to basolateral addition of thrombin (Fig. 9C). As
expected, (mucosal) UTP promoted [3H]inositol phosphate
formation, which was nearly abolished in the presence of
apyrase (Fig. 9C).
DISCUSSION
By examining the effects of PAR and P2Y-R agonists, we
demonstrated that Rho/Rho kinases, in concert with cytosolic
Ca2, are important regulators of ATP release. We also dem-
onstrated that connexin/pannexin hemichannels are likely
effectors of Rho/ROCK and Ca2 signaling pathways that
mediate ATP release from lung epithelial cells. An additional
novel finding was that thrombin actions on A549 cells are
mediated by PAR3, a poorly characterized thrombin recep-
tor subtype.
Our data, indicating that BAPTA and thapsigargin impaired
ATP release from thrombin-stimulated A549 cells, are consist-
entwith the notion that Ca2mobilization is necessary forATP
release. However, ATP release in response to Ca2-mobilizing
agents (e.g. UTP and ionomycin) represented a minor fraction
relative to that observed with thrombin stimulation (Fig. 4).
Thrombin-promoted ATP release decreased in cells trans-
fected with dominant negative mutants of p115-RhoGEF and
RhoA as well as in cells exposed to ROCK inhibitors (Fig. 6).
Thus, Rho GTPases are key regulators of PAR-elicited ATP
release. Importantly, Rho activation itself promoted no ATP
release when temporarily dissociated from Ca2 mobilization.
Therefore, Rho signaling is an obligatory partner of Ca2mobi-
lization upstream of ATP release in A549 cells.
Our present results are also consistent with previous studies
implicating Rho as modulator of ATP release. Ito and cowork-
FIGURE 9. Thrombin-promoted ATP release and inositol phosphate formation in primary HBE cells.
A, well differentiated primary HBE cells were incubated for 5 min with 30 nM thrombin (basolateral), 100 M UTP
(apical), or vehicle; ATP released to the apical or basolateral (BL) medium was quantified, as indicated under
“Experimental Procedures.” B, HBE cells were preincubated bilaterally (1 h) with 1 M H1152, 10 M ML-7 or1 M
CBX, and apical ATP release was measured after 5-min incubation with 30 nM thrombin (basolateral addition) or
vehicle. C, [3H]inositol-labeled HBE cells were incubated for 20 min in the presence of vehicle, 30 nM thrombin
(basolateral addition), 100 M UTP (apical addition), and in the absence or presence of 5 U/ml apyrase (apical
addition). The resulting [3H]inositol phosphates were quantified as indicated under “Experimental Proce-
dures.” The data (mean  S.D.) represent the net increase in counts above background, and they are repre-
sentative of two separate experiments with independent cultures performed each with quadruplicate sam-
ples. *, indicates significant difference between apyrase-treated versus non-treated cultures, p  0.01.
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ers illustrated that Y26632 impaired lysophosphatidic acid-
and/or hypotonic challenge-promoted ATP release in human
umbilical vein and bovine aortic endothelial cells (61, 62). In a
recent report, Blum et al. (26) illustrated that inactivation of
RhoGTPases with Clostridium botulinum C3 exoenzyme im-
paired thrombin- and lysophosphatidic acid-promoted Ca2-
dependent ATP release from 1321N1 astrocytoma cells . How-
ever, Y26632 and ML-7 had no effect on ATP release in these
cells, suggesting that Rho regulation of ATP release in 1321N1
astrocytoma cells occurred independently of ROCK and MLC
phosphorylation. Unlike 1321N1 cells, Y26632, H1152, and
ML-7 impaired thrombin-evoked ATP release in A549 cells.
Although Rho activation may utilize downstream effectors in
addition to ROCK (63), our results suggest that ROCK is an
important regulator of ATP release fromA549 cells. Moreover,
our data suggest that Ca2- and Rho/ROCK-dependent ATP
release from thrombin-stimulated A549 cells occurs via con-
nexin or pannexin hemichannels, a pathway that appeared not
competent for ATP release in 1321N1 astrocytoma cells (26).
Specifically, in A549 cells: (i) thrombin-promoted ATP release
was inhibited by connexin/pannexin inhibitors, (ii) thrombin
promoted the uptake of propidium iodide, an indicator of non-
selective pore opening, which was inhibited by connexin/
pannexin inhibitors, and (iii) thrombin-elicited dye uptake was
inhibited by ROCK and MLCK inhibitors and by BAPTA-AM.
Our study did not address the identity of the putative
hemichannel involved in ATP release. Based on the effect of
[Ca2]ex, connexin hemichannels likely are expressed at the
plasmamembrane of A549 cells. However, whether a connexin
or pannexin hemichannel was responsible for the release of
ATP in physiologically relevant [Ca2]ex, as well as the mecha-
nism potentially involved in hemichannel activation, remain to
be investigated.
A surprising finding in our study was that thrombin actions
in A549 cells could not be associated with PAR1. Although we
have recently reported that the PAR1 peptide TFLLRNPNDK
promoted nucleotide release and inositol phosphate formation
in 1321N1 human astrocytoma cells (25), TFLLRNPNDK failed
to promote these responses in A549 cells. Moreover, A549 cells
used in the current study do not express PAR1 transcripts (Fig.
1). Our data also suggest that PAR4 is not expressed in A549
cells (Fig. 1). The finding that thrombin actions on A549 cells
were not mediated by PAR1 or PAR4 was striking, because the
ability of PAR3 (the other member of the thrombin receptor
family) to generate intracellular signaling has been questioned
(36). The finding that murine PAR3 functions as a cofactor for
proteolytic activation of PAR4 in platelets has reinforced the
assumption that PAR3 does not signal by itself. However, this
observation may also reflect cell type- and species-specific
functions for distinct PARs (reviewed in Ref. 42). Expression of
human PAR3 (but not empty vector) in COS-7 cells resulted in
thrombin-evoked inositol phosphate formation (36), likely via
Gq-mediated phospholipase C activation. In addition, co-ex-
pression of G16 (a G protein endogenously expressed in hema-
topoietic cells that promiscuously transduces GPCR activation
into phospholipase C activation) also conferred enhanced and
potent thrombin-promoted inositol phosphate formation to
PAR3-transfected COS-7 cells (36).
Unlike other PARs, evidence that natively expressed PAR3
promotes cellular responses by its own is scarce. For example,
Ostrowska and Reiser recently illustrated that thrombin, but
not a PAR1 peptide, promoted interleukin-8 secretion from
both lung epithelial and astrocytoma cells, and that silencing
PAR1 and PAR3 simultaneously (but not PAR1 alone) resulted
in reduced interleukin-8 production in astrocytoma cells. The
authors suggested thrombin actions were mediated by PAR3
(64). McLaughlin et al. reported that thrombin-elicited
transendothelial electrical resistance was mediated in part by
PAR3, which (together with PAR1) is endogenously expressed
in human endothelial cells. PAR3 suppression resulted in50%
reduction of transendothelial electrical resistance, while PAR1
suppression completely reduced transendothelial electrical
resistance in response to thrombin. Based on bioluminescent
resonance energy transfer-2 measurements, the authors con-
cluded that PAR3 dimerizes with and regulates PAR1 signaling
(65). Our data, illustrating that (i) PAR1AP and PAR4AP fail to
promote cellular responses in A549 cells, (ii) PAR3 is the only
PAR transcript present in these cells, and (iii) PAR3 siRNA
decreased thrombin-evoked responses, indicate that PAR3 is
themajor thrombin receptor functionally present in these cells.
Moreover, the observation that PAR3 overexpression
enhanced thrombin-elicited inositol phosphate formation,
RhoA activation, and ATP release, strongly suggest that PAR3
is capable of triggering signaling. Collectively, our results dem-
onstrate that thrombin actions on A549 cells are mediated by
PAR3-promoted Ca2 mobilization and Rho activation, and
that these signaling cascades must be temporally coordinated
to allow ATP release via connexin/pannexin hemichannel
opening.
Key observations obtained with A549 cells were expanded to
physiologically relevant primary cultures of well differentiated
HBE cells. In these cultures, basolateral addition of thrombin
resulted in robustmucosal ATP release, which was inhibited by
ROCK and MLCK inhibitors as well as by connexin/pannexin
hemichannel blockers (Fig. 9, A and B). In addition, measure-
ments of [3H]inositol phosphate formation in thrombin-stim-
ulated HBE cells suggested a previously unnoticed autocrine
action of released ATP, i.e. as a contributor to PAR-evoked
signaling (Fig. 9C). In summary, our study is the first to dem-
onstrate the occurrence of robust ATP release in GPCR ago-
nist-stimulated human airway epithelial cells and to implicate
the participation of ROCK and MLCK as potential upstream
effectors of ATP release via connexin/pannexin hemichannels.
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